Merck & Company Inc (MRK)vsMeridian Bioscience Inc (VIVO)
MRK
Merck & Company Inc
$114.18
-0.02%
HEALTHCARE · Cap: $285.39B
VIVO
Meridian Bioscience Inc
$2.24
-5.49%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 19422% more annual revenue ($65.01B vs $333.02M). MRK leads profitability with a 28.1% profit margin vs 12.8%. VIVO appears more attractively valued with a PEG of 1.33. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
VIVO
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-130.7%
Fair Value
$49.50
Current Price
$114.18
$64.68 premium
Margin of Safety
N/A
Fair Value
$6.53
Current Price
$2.24
$4.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Revenue declined 13.8%
Earnings declined 13.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : VIVO
The strongest argument for VIVO centers on Price/Book, Operating Margin. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VIVO
The primary concerns for VIVO are P/E Ratio, Market Cap, Revenue Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while VIVO is a declining play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.26 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 48/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Meridian Bioscience Inc
HEALTHCARE · PHARMACEUTICALS · USA
Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?